RXi Pharmaceuticals Corp. Company Profile (NASDAQ:RXII)

About RXi Pharmaceuticals Corp.

RXi Pharmaceuticals Corp. logoRXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, primarily in the areas of dermatology and ophthalmology. The Company's development programs are based on its siRNA technology and immunotherapy agents. Its clinical development programs include self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring, and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RXII
  • CUSIP:
Key Metrics:
  • Previous Close: $2.40
  • 50 Day Moving Average: $2.38
  • 200 Day Moving Average: $2.48
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.86
  • P/E Growth: 0.00
  • Market Cap: $15.74M
  • Outstanding Shares: 6,559,000
  • Beta: 0.92
Additional Links:
Companies Related to RXi Pharmaceuticals Corp.:

Analyst Ratings

Consensus Ratings for RXi Pharmaceuticals Corp. (NASDAQ:RXII) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (45.83% upside)

Analysts' Ratings History for RXi Pharmaceuticals Corp. (NASDAQ:RXII)
Show:
DateFirmActionRatingPrice TargetDetails
6/7/2016HC WainwrightInitiated CoverageBuy$3.50View Rating Details
(Data available from 8/23/2014 forward)

Earnings

Earnings History for RXi Pharmaceuticals Corp. (NASDAQ:RXII)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/11/2016Q216($0.36)($0.34)ViewListenView Earnings Details
5/13/2016Q116($0.45)($0.34)$34.00 million$10.00 millionViewListenView Earnings Details
3/30/2016Q415($0.05)($0.04)ViewListenView Earnings Details
11/12/2015Q315($0.04)($0.04)ViewListenView Earnings Details
8/12/2015Q215($0.09)($0.05)ViewListenView Earnings Details
5/13/2015Q115($0.10)($0.13)ViewListenView Earnings Details
3/30/2015Q414($0.14)($0.13)ViewN/AView Earnings Details
11/13/2014Q314($0.22)($0.17)ViewN/AView Earnings Details
8/14/2014Q214($0.25)($0.23)ViewN/AView Earnings Details
5/14/2014Q114($0.31)($0.32)ViewN/AView Earnings Details
3/28/2014($0.31)$0.84ViewN/AView Earnings Details
11/14/2012Q312($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RXi Pharmaceuticals Corp. (NASDAQ:RXII)
Current Year EPS Consensus Estimate: $-1.50 EPS
Next Year EPS Consensus Estimate: $-1.29 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RXi Pharmaceuticals Corp. (NASDAQ:RXII)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RXi Pharmaceuticals Corp. (NASDAQ:RXII)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/2/2015Geert CauwenberghCEOBuy5,000$0.72$3,600.00View SEC Filing  
2/17/2015Geert CauwenberghCEOBuy4,000$1.17$4,680.00View SEC Filing  
2/10/2015Geert CauwenberghCEOBuy2,000$1.24$2,480.00View SEC Filing  
1/22/2015Robert J BittermanDirectorBuy5,000$1.20$6,000.00View SEC Filing  
1/20/2015Geert CauwenberghCEOBuy10,000$1.03$10,300.00View SEC Filing  
12/30/2014Geert CauwenberghCEOBuy2,500$1.59$3,975.00View SEC Filing  
10/13/2014Geert CauwenberghCEOBuy3,000$1.68$5,040.00View SEC Filing  
9/19/2014Geert CauwenberghCEOBuy4,500$2.20$9,900.00View SEC Filing  
9/16/2014Geert CauwenberghCEOBuy5,000$2.08$10,400.00View SEC Filing  
9/15/2014Geert CauwenberghCEOBuy10,000$2.18$21,800.00View SEC Filing  
7/15/2014Geert CauwenberghCEOBuy1,000$2.50$2,500.00View SEC Filing  
7/9/2014Geert CauwenberghCEOBuy1,400$2.57$3,598.00View SEC Filing  
7/2/2014Geert CauwenberghCEOBuy2,000$2.86$5,720.00View SEC Filing  
6/19/2014Geert CauwenberghCEOBuy2,000$2.98$5,960.00View SEC Filing  
6/9/2014Geert CauwenberghCEOBuy1,000$3.05$3,050.00View SEC Filing  
6/4/2014Geert CauwenberghCEOBuy2,000$2.94$5,880.00View SEC Filing  
10/31/2013Geert CauwenberghCEOBuy1,000$3.17$3,170.00View SEC Filing  
10/23/2013Geert CauwenberghCEOBuy1,000$3.34$3,340.00View SEC Filing  
10/9/2013Geert CauwenberghCEOBuy1,000$3.15$3,150.00View SEC Filing  
8/29/2013Curtis LockshinDirectorBuy1,000$3.70$3,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for RXi Pharmaceuticals Corp. (NASDAQ:RXII)
DateHeadline
investornewswire.com logoWill RXI Pharmaceuticals Corporation (NASDAQ:RXII) Hit $25 Price Target? - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - August 22 at 11:50 AM
seekingalpha.com logoRXI Pharmaceuticals' (RXII) CEO Geert Cauwenbergh on Q2 2016 Results - Earnings Call Transcript (NASDAQ:RXII)
seekingalpha.com - August 12 at 10:29 AM
rttnews.com logoEARNINGS SUMMARY: Details of RXi Pharmaceuticals Corp. Q2 Earnings Report (NASDAQ:RXII)
www.rttnews.com - August 11 at 10:33 AM
finance.yahoo.com logoRXi Pharmaceuticals Reports Second Quarter 2016 Financial Results and Highlights Recent Corporate Developments (NASDAQ:RXII)
finance.yahoo.com - August 11 at 10:33 AM
investing.com logoRXi Pharmaceuticals: Samcyprone Data At AAD (NASDAQ:RXII)
www.investing.com - August 4 at 7:43 PM
ftsenews.co.uk logoRXI Pharmaceuticals Corporation (RXII) Updated Price Targets - FTSE News (NASDAQ:RXII)
www.ftsenews.co.uk - August 4 at 10:26 AM
finance.yahoo.com logoRXi Pharmaceuticals to Webcast Second Quarter 2016 Financial Results on Thursday, August 11, 2016 (NASDAQ:RXII)
finance.yahoo.com - July 28 at 7:02 AM
prnewswire.com logoRXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology - PR Newswire (press release) (NASDAQ:RXII)
www.prnewswire.com - July 21 at 10:05 AM
finance.yahoo.com logoRXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology (NASDAQ:RXII)
finance.yahoo.com - July 21 at 7:02 AM
capitalcube.com logoETF’s with exposure to RXi Pharmaceuticals Corp. : July 20, 2016 (NASDAQ:RXII)
www.capitalcube.com - July 20 at 12:51 PM
News IconRxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorts Decreased by 5.68% After Short Covering - Press Telegraph (NASDAQ:RXII)
presstelegraph.com - July 19 at 8:21 AM
investornewswire.com logoStrong Sell Calls For RXI Pharmaceuticals Corporation (NASDAQ:RXII) At 0 - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - July 17 at 6:38 PM
News IconShares Moving Down on the Week: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Engelwood Daily (NASDAQ:RXII)
www.engelwooddaily.com - July 17 at 11:19 AM
News IconRxi Pharmaceuticals Corp Sentiment Improves on Better Stock Potential - Press Telegraph (NASDAQ:RXII)
presstelegraph.com - July 15 at 12:27 PM
kcregister.com logoCincinnati Bell Inc. (NYSE:CBB) increased 4.39%: RXi Pharmaceuticals Corporation (NASDAQ:RXII), Magellan ... - KC Register (NASDAQ:RXII)
www.kcregister.com - July 12 at 11:37 AM
investornewswire.com logoIs $25 Within Reach For RXI Pharmaceuticals Corporation (NASDAQ:RXII)? - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - July 10 at 6:28 PM
fiscalstandard.com logoBrokers Issue Average Price Target Of 4.08 On RXI Pharmaceuticals Corporation (RXII) - Fiscal Standard (NASDAQ:RXII)
www.fiscalstandard.com - July 10 at 11:14 AM
News IconRxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorted Shares Decreased By 5.68% - Press Telegraph (NASDAQ:RXII)
presstelegraph.com - July 7 at 7:19 PM
News IconShare Volatility in Focus: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Engelwood Daily (NASDAQ:RXII)
www.engelwooddaily.com - July 6 at 11:51 AM
News IconCompany Stock Lower on the Week RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Engelwood Daily (NASDAQ:RXII)
www.engelwooddaily.com - July 3 at 11:22 AM
investornewswire.com logoStrong Sell Calls Recommendations For RXI Pharmaceuticals Corporation (NASDAQ:RXII) At 0 - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - June 27 at 11:23 AM
News IconShare Volatility Check for: RXi Pharmaceuticals Corporation (NASDAQ:RXII) - Press Telegraph (NASDAQ:RXII)
presstelegraph.com - June 24 at 7:19 PM
investornewswire.com logoStrong Buy Calls Count For RXI Pharmaceuticals Corporation (NASDAQ:RXII) At 2 - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - June 21 at 11:34 AM
fiscalstandard.com logoThis Weeks Broker Views For RXI Pharmaceuticals Corporation (RXII) - Fiscal Standard (NASDAQ:RXII)
www.fiscalstandard.com - June 21 at 11:34 AM
investornewswire.com logoTrend Of Rating Given To RXI Pharmaceuticals Corporation (NASDAQ:RXII) - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - June 13 at 10:11 AM
capitalcube.com logoRXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 (NASDAQ:RXII)
www.capitalcube.com - June 6 at 12:11 PM
News IconNext Weeks Broker Price Targets For RXI Pharmaceuticals Corporation (RXII) - Share Trading News (NASDAQ:RXII)
www.sharetrading.news - May 31 at 7:19 AM
News IconRxi Pharmaceuticals Corporation (NASDAQ:RXII) Sellers Increased By 13.42% Their Shorts - HNN (NASDAQ:RXII)
hintsnewsnetwork.com - May 30 at 8:05 AM
investornewswire.com logoRXI Pharmaceuticals Corporation (NASDAQ:RXII) Closes At $2.17 - Investor Newswire (NASDAQ:RXII)
www.investornewswire.com - May 27 at 10:19 PM
News IconRxi Pharmaceuticals Corporation (NASDAQ:RXII) Shorts Decreased by 21.16% After Short Covering - Wall Street Hints and News (NASDAQ:RXII)
hintsnewsnetwork.com - May 26 at 8:04 AM
News IconPreview of HC Stock's Movement: Immunomedics, Inc. (NASDAQ:IMMU), RXi Pharmaceuticals Corp (NASDAQ:RXII) - share market updates (press release) (NASDAQ:RXII)
sharemarketupdates.com - May 23 at 9:43 AM
News IconAfter Last Week What Do Analysts Think Of RXI Pharmaceuticals Corporation (RXII) - Share Trading News (NASDAQ:RXII)
www.sharetrading.news - May 22 at 9:34 PM
tradecalls.org logoRevenue Update on RXi Pharmaceuticals Corp(NASDAQ:RXII) - Trade Calls (NASDAQ:RXII)
www.tradecalls.org - May 20 at 9:58 PM
finance.yahoo.com logoRXI PHARMACEUTICALS CORP Financials (NASDAQ:RXII)
finance.yahoo.com - May 20 at 1:04 PM
realistinvestor.com logoAlpha One Assigns Impact Score Of 0 To RXI Pharmaceuticals Corporation (NASDAQ:RXII) - RealistInvestor.com (NASDAQ:RXII)
www.realistinvestor.com - May 19 at 9:58 PM
News IconHC Stocks in Hub: CTI BioPharma Corp (CTIC), CytRx Corporation (CYTR), RXi Pharmaceuticals Corp (RXII) - share market updates (press release) (NASDAQ:RXII)
sharemarketupdates.com - May 12 at 5:09 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:RXII)
biz.yahoo.com - May 12 at 7:18 AM
biz.yahoo.com logoQ1 2016 Rxi Pharmaceuticals Corp Earnings Release - After Market Close (NASDAQ:RXII)
biz.yahoo.com - May 12 at 7:07 AM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report (NASDAQ:RXII)
biz.yahoo.com - May 12 at 7:03 AM
finance.yahoo.com logoRXi Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Corporate Developments (NASDAQ:RXII)
finance.yahoo.com - May 12 at 7:02 AM
finance.yahoo.com logoRXi Pharmaceuticals Provides Strategic Update (NASDAQ:RXII)
finance.yahoo.com - May 10 at 6:55 AM
News IconLatest Analyst Ratings For RXI Pharmaceuticals Corporation (RXII) - Share Trading News (NASDAQ:RXII)
www.sharetrading.news - May 5 at 5:19 PM
biz.yahoo.com logoRXI PHARMACEUTICALS CORP Files SEC form 8-K, Other Events (NASDAQ:RXII)
biz.yahoo.com - May 4 at 4:44 PM
finance.yahoo.com logoRXi Pharmaceuticals to Present an Update on its Consumer Health Programs at the Society for Investigative Dermatology 75th Annual Meeting (NASDAQ:RXII)
finance.yahoo.com - May 4 at 7:02 AM
finance.yahoo.com logoRXi Pharmaceuticals and Thera Neuropharma Enter into an Exclusive License Agreement for RXi's Self-Delivering RNAi (sd-rxRNA®) Platform Targeting SOD1 to Develop Therapeutics for Neurodegenerative Diseases, such as ALS (Lou Gehrig's Disease (NASDAQ:RXII)
finance.yahoo.com - May 3 at 7:12 AM
News IconBroker Outlook For The Week Ahead: RXI Pharmaceuticals Corporation (RXII) - Share Trading News (NASDAQ:RXII)
www.sharetrading.news - May 2 at 5:24 PM
finance.yahoo.com logoRXi Pharmaceuticals Secures European Patent for Novel RNAi Platform (NASDAQ:RXII)
finance.yahoo.com - May 2 at 7:02 AM
streetinsider.com logoRXI Pharma (RXII) Announces New, Positive Data for RXI-109 in Late-Stage AMD (NASDAQ:RXII)
www.streetinsider.com - April 30 at 5:04 PM
streetinsider.com logoRXI Pharma (RXII) Announces New, Positive Data for RXI-109 in Late-Stage AMD - StreetInsider.com (NASDAQ:RXII)
www.streetinsider.com - April 28 at 5:25 PM
finance.yahoo.com logoRXi Pharmaceuticals Announces Advancement of its Ophthalmology Franchise with Successful Topical Delivery of sd-rxRNA to the Cornea in an in vivo Corneal Wound Model (NASDAQ:RXII)
finance.yahoo.com - April 28 at 7:02 AM

Social

RXi Pharmaceuticals Corp. (NASDAQ:RXII) Chart for Tuesday, August, 23, 2016


Last Updated on 8/23/2016 by MarketBeat.com Staff